乌帕替尼再诱导与高剂量维持治疗炎症性肠病的真实世界经验
这项前瞻性队列研究纳入181例对乌帕替尼45mg每日一次诱导有应答后减量维持的炎症性肠病患者,其中46例减量后失应答并接受45mg再诱导。再诱导中位13周后80.4%重获临床应答;继续45mg维持者93.8%维持缓解,再次减量者仅21.1%(P<.001)。痤疮/酒渣鼻最常见(39%),无严重不良事件。
要点
- 减量后失应答者用45mg再诱导,80.4%可重获应答。
- 再诱导后继续45mg维持,93.8%维持缓解,显著优于再次减量。
- 病变范围和病程未显著预测应答重获。
核心结论
- 减量维持失应答的IBD患者,45mg每日一次再诱导多可重获应答,继续45mg维持有效且看似安全。
研究设计与样本
- 前瞻性队列研究,2022年4月至2023年11月接受乌帕替尼治疗的IBD患者。
- 181例对45mg诱导有应答并减量维持,其中46例减量后失应答并接受45mg再诱导。
- 随访中位93周(IQR 62-119周),采用比较统计与Kaplan-Meier生存分析。
主要发现
- 减量后中位21周(IQR 8-46周)复发。
- 45mg再诱导中位13周(IQR 8-36周),80.4%重获临床应答。
- 重获应答者中19例再次减至30mg或15mg。
- 中位40周(IQR 22-59周)内,45mg维持者93.8%维持缓解,再次减量者21.1%(P<.001)。
- 病变范围和病程未显著预测应答重获;痤疮/酒渣鼻最常见(39%),无严重不良事件。
临床怎么用
- 对乌帕替尼减量维持后失应答的IBD患者,可考虑45mg每日一次再诱导。
- 再诱导重获应答后继续45mg每日一次维持可能优于再次减量。
局限性
- 再诱导分析样本量较小(46例)。
- 单中心真实世界研究,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Upadacitinib (UPA) is approved for the treatment of moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). Responders to UPA 45 mg daily (QD) may lose response (LOR) after transition to lower maintenance doses. We describe our real-world experience of LOR, reinduction, and subsequent maintenance with UPA 45 mg QD. METHODS: This is a prospective cohort study of patients with inflammatory bowel disease (IBD) treated with UPA between April 2022 and November 2023. Included patients responded to UPA induction, had LOR after dose reduction, and subsequently received reinduction therapy with 45 mg QD. Clinical, biochemical, radiologic, and endoscopic data were collected; comparative statistics and Kaplan-Meier survival were calculated. RESULTS: A total of 181 patients (79 CD, 83 UC, 6 IBD-Unclassified, 13 ileal pouch anal-anastomosis) responded to UPA 45 mg QD induction and were switched to a lower maintenance dose (30 mg QD, n = 180; 15 mg QD, n = 1), 46 (16 CD, 23 UC, 1 IBD- Unclassified, 6 ileal pouch anal-anastomosis) met the above criteria. They were followed for a median duration 93 weeks (interquartile range [IQR], 62-119 weeks). Relapse occurred at a median of 21 weeks (IQR, 8-46 weeks) after dose reduction. Dose escalation to 45 mg QD for a median of 13 weeks (IQR, 8-36 weeks) recaptured clinical response in 80.4%. Among patients who recaptured response, 19 again reduced to 30 mg or 15 mg. Over a median of 40 weeks (IQR, 22-59 weeks), 93.8% of patients on 45 mg QD maintained remission vs 21.1% who again dropped to 30 mg QD (P < .001). Disease extent and duration did not significantly predict response recapture. Acne/rosacea was the most common adverse event (39%); there were no serious adverse events. CONCLUSIONS: Most patients with IBD who lose response to UPA when dose reduced in maintenance can be recaptured with 45 mg QD. Among these, continuing 45 mg QD for maintenance is effective, and appears safe.
引用
- Ho AHY, Choi D, Mathew AJ, et al. Real-world Experience of Upadacitinib Reinduction and High-dose Maintenance Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40782945. doi:10.1016/j.cgh.2025.07.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。